title: Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment.
abstract: OBJECTIVE
  To investigate the impact of functional ovarian cysts on the time required to achieve pituitary suppression, follicular development, embryo quality, and pregnancy rates during IVF treatment.
  
  
  METHODS
  Prospective observational study.
  
  
  METHODS
  Daily treatment with buserelin (sc 500 microg) was initiated on day 2 of menstruation. Ultrasound and hormonal tests were performed on days 1, 7, 11, 14, and weekly thereafter until pituitary suppression was achieved.
  
  
  RESULTS
  48 patients underwent 51 cycles of IVF treatment. A functional cyst was detected in three cycles (5.8%) with baseline ultrasound scan and in 27 cycles (52.9%) on day 7 of buserelin administration. Patients who developed a cyst required a significantly longer time to achieve pituitary suppression (21 vs. 7 days), had a significantly lower FSH level at the time of initiation of gonadotropins, required more ampules of gonadotropin (45 vs. 41 ampules), developed less follicles (13 vs. 17.5), and had lower embryo quality. However, there were no differences in the implantation (23.5% vs. 17.2%) and pregnancy rates (37.2% vs. 29.2%) between two groups.
  
  
  CONCLUSIONS
  Functional cysts prolong the period to achieving pituitary suppression, increase gonadotropin requirements, and decrease follicular recruitment and embryo quality. They have, however, no negative effect on pregnancy rates.
authors.affiliation: McGill Reproductive Center, Department of Obstetrics and Gynecology, Royal Victoria Hospital, McGill University, Montreal, Québec, Canada. mbiljan@rvhob2.lan.mcgill.ca
authors.forename: M M
authors.initials: MM
authors.lastname: Biljan
authors.forename: L
authors.initials: L
authors.lastname: Lapensée
authors.forename: N G
authors.initials: NG
authors.lastname: Mahutte
authors.forename: F
authors.initials: F
authors.lastname: Bissonnette
authors.forename: R
authors.initials: R
authors.lastname: Hemmings
authors.forename: S L
authors.initials: SL
authors.lastname: Tan
mesh_terms: D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects* / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D010048:Ovarian Cysts / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin